Moderna Shares Rebound After Pullback Following Cancer Vaccine Rally

MRK and MRNA's intismeran autogene showed positive Phase 3 results in melanoma, beating Keytruda alone on recurrence-free survival. BNTX rose 21.6%, ILMN 15.6%, PACB 5.8%, RGEN and DHR also mentioned. Analysts project varying revenue forecasts for the therapy. Keytruda's U.S. patent cliff is in 2028, with 2025 sales at $31.641B.

Moderna (MRNA) stock rose 2.9% in pre-market trading after a multi-session pullback. The rally follows successful Phase 3 trial results for its mRNA cancer vaccine, intismeran, in partnership with Merck. Barclays raised its price target to $125, while Wolfe Research estimated peak sales of $9.2B across four indications. The broader market's risk-on tone also supported the rebound.

Arbutus Biopharma (ABUS) shares rose 6% as Moderna (MRNA) is set to make a $950M upfront payment by July 8 under a $2.25B settlement, with ABUS receiving ~$179M. The dispute involved patented lipid nanoparticle technology used in Moderna's COVID-19 vaccine. ABUS also progresses its hepatitis B drug, imdusiran, with FDA Fast Track designation. Analysts rate ABUS a 'buy' with a $5.14 avg. price target.

Merck & Co. and Moderna Inc. reported positive results from a late-stage trial of their mRNA cancer vaccine, intismeran, combined with Keytruda, showing it delayed melanoma recurrence. Moderna's stock more than doubled on the news. The trial marks a significant step for cancer vaccines, though further research is needed for other cancer types. The companies did not disclose specific efficacy data.

Merck (MRK) and Moderna (MRNA) announced positive Phase 3 trial results for their personalized cancer vaccine, Intismeran, in combination with Keytruda for melanoma. Merck's shares surged 12.5%, adding $43 billion to its market value. Analysts raised price targets, citing the vaccine's potential to offset Keytruda's patent expiration in 2028. Goldman Sachs, UBS, and Bank of America increased their targets, while RBC Capital downgraded the stock.

Moderna (MRNA) and Merck (MRK) announced positive Phase 3 trial results for their personalized cancer vaccine, Intismeran, showing significant improvement in treating melanoma. Moderna's stock surged 177% in a single day. The companies are conducting further trials across various cancers. The treatment represents a breakthrough in personalized medicine, potentially leading to FDA approval.